Luye Pharma Group Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
6/10
|
22.58 | 35.42 | -36.24% | -8.3 | -372.17% |
| P/S |
|
1.96 | 7.59 | -74.2% |
|
|
| P/BV |
|
0.8891 | 3.68 | -75.87% |
|
|
| P/FCF |
|
27.54 | 55.41 | -50.29% |
|
|
| Ev/Ebitda |
|
11.08 | 2.91 | 281% |
|
|
| Ev/S |
|
2.4 | 23.72 | -89.89% |
|
|
| Ev/FCF |
|
34.23 | 63.79 | -46.34% |
|
|
| E/P |
|
0.0449 | 0.0326 | 37.68% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
9/10
|
30.31 | -11.9 | -354.67% | 27.87 | 8.74% |
| ROE |
|
4.69 | 5.19 | -9.55% |
|
|
| ROA |
|
2.14 | 3.47 | -38.28% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
8.67 | -11.49 | -175.48% |
|
|
| ROCE |
|
0 | 6.04 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
0/10
|
5.07 | 0.7755 | 553.72% | 9.48 | -46.5% |
| Nеt Debt/Ebitda |
|
1.49 | 0.0128 | 11568.44% |
|
|
| Debt/Ratio |
|
0.3605 | 0.1229 | 193.46% |
|
|
| Debt/Equity |
|
1.87 | 0.8001 | 133.94% |
|
|
| Debt/Net Income |
|
17.25 | 1.76 | 881.76% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 2.42 | -100% | 1.43 | -100% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% |
|
|
| DSI |
|
0.75 | 0.563 | 33.22% |
|
|
| Average dividend growth |
|
10.12 | 3.2 | 216.07% |
|
|
| Average percentage for 5 years |
|
1.43 | 1.82 | -21.24% |
|
|
| Average percentage for payments |
|
21.89 | 23.96 | -8.66% |
|
|
| Difference from average difference in sector |
|
-2.42 |
|
|
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % |
|---|---|---|---|---|
| Growth impulse Revenue 5 years |
0/10
|
-3.37 | 19.4 | -117.37% |
| Growth impulse Ebitda 5 years |
|
-1.15 | -44.8 | -97.43% |
| Growth impulse Net Income 5 years |
|
-63.73 | 80.79 | -178.88% |
| Growth impulse FCF 5 years |
|
-129.11 | 76.43 | -268.93% |
| Growth impulse EPS 5 years |
|
-72.71 | -116.84 | -37.77% |
IP Score
3.62/10
